ZA201807585B - Combination therapy with notch and pd-1 or pd-l1 inhibitors - Google Patents
Combination therapy with notch and pd-1 or pd-l1 inhibitorsInfo
- Publication number
- ZA201807585B ZA201807585B ZA2018/07585A ZA201807585A ZA201807585B ZA 201807585 B ZA201807585 B ZA 201807585B ZA 2018/07585 A ZA2018/07585 A ZA 2018/07585A ZA 201807585 A ZA201807585 A ZA 201807585A ZA 201807585 B ZA201807585 B ZA 201807585B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- lymphoblastic leukemia
- oxo
- carcinoma
- treating
- Prior art date
Links
- 239000012271 PD-L1 inhibitor Substances 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 title abstract 2
- 239000012270 PD-1 inhibitor Substances 0.000 title 1
- 239000012668 PD-1-inhibitor Substances 0.000 title 1
- 229940121655 pd-1 inhibitor Drugs 0.000 title 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 241000288575 Astomaea Species 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010059352 Desmoid tumour Diseases 0.000 abstract 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 abstract 1
- 208000036566 Erythroleukaemia Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 abstract 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 abstract 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 208000021841 acute erythroid leukemia Diseases 0.000 abstract 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 abstract 1
- 229960003852 atezolizumab Drugs 0.000 abstract 1
- 229950002916 avelumab Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 201000006827 desmoid tumor Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229950009791 durvalumab Drugs 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960003301 nivolumab Drugs 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 229960002621 pembrolizumab Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339363P | 2016-05-20 | 2016-05-20 | |
| PCT/US2017/032790 WO2017200969A1 (en) | 2016-05-20 | 2017-05-16 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201807585B true ZA201807585B (en) | 2024-09-25 |
Family
ID=58772978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/07585A ZA201807585B (en) | 2016-05-20 | 2018-11-12 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10688104B2 (enExample) |
| EP (1) | EP3458091B1 (enExample) |
| JP (1) | JP7194022B2 (enExample) |
| KR (1) | KR102463617B1 (enExample) |
| CN (2) | CN115845070A (enExample) |
| AU (1) | AU2017268187A1 (enExample) |
| BR (1) | BR112018073673A2 (enExample) |
| CA (1) | CA3025024A1 (enExample) |
| ES (1) | ES2904880T3 (enExample) |
| IL (1) | IL263110B (enExample) |
| MA (1) | MA45025A (enExample) |
| MX (1) | MX2018013941A (enExample) |
| SG (1) | SG11201810268YA (enExample) |
| WO (1) | WO2017200969A1 (enExample) |
| ZA (1) | ZA201807585B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| MX380779B (es) | 2016-04-12 | 2025-03-12 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6 |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| CN111727060B (zh) * | 2017-12-18 | 2023-04-11 | 德彪药业国际股份公司 | 治疗癌症的激动剂抗PD-1抗体与GnRH激动剂或GnRH拮抗剂的组合 |
| KR20220114532A (ko) * | 2019-10-28 | 2022-08-17 | 주식회사 엔지켐생명과학 | 암의 치료를 위한 방법 및 조성물 |
| AU2021443620A1 (en) * | 2021-04-28 | 2023-10-26 | Obi Pharma, Inc. | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001232A3 (en) | 1996-12-23 | 2001-02-28 | Elan Pharmaceuticals Inc San F | Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds |
| AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| DE102006002966A1 (de) * | 2006-01-21 | 2007-07-26 | Schaeffler Kg | Laufscheibe mit integrierter Wälzkörperlaufbahn |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| CN101674834B (zh) | 2007-03-28 | 2013-06-12 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton's tyrosine kinase)抑制剂 |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| EP2178844A1 (en) | 2007-08-14 | 2010-04-28 | Eli Lilly & Company | Azepine derivatives as gamma-secretase inhibitors |
| US20090181944A1 (en) | 2008-01-11 | 2009-07-16 | John Frederick Boylan | Method for cancer therapy |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| US20120213029A1 (en) | 2009-08-26 | 2012-08-23 | Frxsh Ag | Apparatus and method for mixing of a material to be mixed |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| DK2504364T3 (da) | 2009-11-24 | 2017-11-06 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| AR087405A1 (es) * | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| SMT202000561T1 (it) | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
| EP3035964B1 (en) * | 2013-08-20 | 2020-09-23 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| WO2016007775A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
| RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
| US9465158B2 (en) * | 2014-09-04 | 2016-10-11 | National Taiwan Normal University | Light-guide coupler for modulating angular and spatial distributions of light source |
| ES2771926T3 (es) * | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| HK1243631A1 (zh) * | 2014-10-27 | 2018-07-20 | Fred Hutchinson Cancer Research Center | 用於提高过继细胞免疫疗法效力的组合物和方法 |
| AU2015338974B2 (en) * | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| BR112017011914A2 (pt) | 2014-12-05 | 2018-02-27 | Memorial Sloan-Kettering Cancer Center | ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso? |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| MX2018000999A (es) | 2015-07-24 | 2018-11-09 | Oncotracker Inc | Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| MX380779B (es) | 2016-04-12 | 2025-03-12 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6 |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| US20190209581A1 (en) | 2016-08-31 | 2019-07-11 | Eli Lilly And Company | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
-
2017
- 2017-05-16 JP JP2018560759A patent/JP7194022B2/ja active Active
- 2017-05-16 KR KR1020187036486A patent/KR102463617B1/ko active Active
- 2017-05-16 CN CN202211692364.1A patent/CN115845070A/zh active Pending
- 2017-05-16 CN CN201780044786.9A patent/CN109475629A/zh active Pending
- 2017-05-16 MA MA045025A patent/MA45025A/fr unknown
- 2017-05-16 EP EP17726073.4A patent/EP3458091B1/en active Active
- 2017-05-16 AU AU2017268187A patent/AU2017268187A1/en not_active Abandoned
- 2017-05-16 ES ES17726073T patent/ES2904880T3/es active Active
- 2017-05-16 CA CA3025024A patent/CA3025024A1/en active Pending
- 2017-05-16 IL IL263110A patent/IL263110B/en unknown
- 2017-05-16 SG SG11201810268YA patent/SG11201810268YA/en unknown
- 2017-05-16 WO PCT/US2017/032790 patent/WO2017200969A1/en not_active Ceased
- 2017-05-16 BR BR112018073673-2A patent/BR112018073673A2/pt unknown
- 2017-05-16 MX MX2018013941A patent/MX2018013941A/es unknown
- 2017-05-16 US US16/301,360 patent/US10688104B2/en active Active
-
2018
- 2018-11-12 ZA ZA2018/07585A patent/ZA201807585B/en unknown
-
2020
- 2020-05-08 US US16/870,853 patent/US11826317B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3025024A1 (en) | 2017-11-23 |
| CN115845070A (zh) | 2023-03-28 |
| KR20190008913A (ko) | 2019-01-25 |
| US20220008432A1 (en) | 2022-01-13 |
| US10688104B2 (en) | 2020-06-23 |
| MX2018013941A (es) | 2019-03-21 |
| CN109475629A (zh) | 2019-03-15 |
| SG11201810268YA (en) | 2018-12-28 |
| WO2017200969A1 (en) | 2017-11-23 |
| BR112018073673A2 (pt) | 2019-02-26 |
| JP7194022B2 (ja) | 2022-12-21 |
| KR102463617B1 (ko) | 2022-11-03 |
| IL263110B (en) | 2022-07-01 |
| IL263110A (en) | 2018-12-31 |
| US11826317B2 (en) | 2023-11-28 |
| JP2019516733A (ja) | 2019-06-20 |
| ES2904880T3 (es) | 2022-04-06 |
| AU2017268187A1 (en) | 2018-11-29 |
| EP3458091B1 (en) | 2021-11-17 |
| EP3458091A1 (en) | 2019-03-27 |
| MA45025A (fr) | 2019-03-27 |
| US20190192531A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807585B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| ZA202309638B (en) | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| JP2019516733A5 (enExample) | ||
| MX380779B (es) | Terapia combinatoria con inhibidores notch y cdk4/6 | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| MX2018012456A (es) | Terapia combinatoria con inhibidores notch y pi3k/mtor. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| IN2014DN11099A (enExample) | ||
| PH12016502354A1 (en) | Pharmaceutical composition | |
| BR112018002941A2 (pt) | métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2020008395A (es) | Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. | |
| MX2021007477A (es) | Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer. | |
| PH12021553177A1 (en) | Pharmaceutical composition for treating tumor | |
| MX2011008132A (es) | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis. | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| NZ596226A (en) | Antitumor combination including cabazitaxel and capecitabine | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| EP4445914A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE | |
| MX2014002817A (es) | Suspension oral. |